Related Experiment Video
Updated: Jul 14, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Posaconazole: a new broad-spectrum antifungal agent
Douglas S Kwon1, Eleftherios Mylonakis
1Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit Street, Boston, MA 02114-2696, USA.
Novel antifungal posaconazole shows promise for treating and preventing invasive fungal infections, including candidiasis and aspergillosis, in immunocompromised patients. Its broad-spectrum activity makes it a valuable addition to antifungal treatments.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Rising incidence of invasive fungal infections.
- Emergence of antifungal resistance necessitates new treatments.
- Need for novel antifungal agents with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy and safety of posaconazole.
- To assess posaconazole's role in treating various fungal infections.
- To determine posaconazole's utility in prophylaxis for immunocompromised patients.
Main Methods:
- Review of in vitro studies, animal models, and clinical trials.
- Assessment of posaconazole's efficacy in oropharyngeal candidiasis.
- Evaluation of posaconazole as salvage therapy for invasive aspergillosis, zygomycosis, and cryptococcal meningitis.
Main Results:
- Posaconazole demonstrated clinical efficacy in oropharyngeal candidiasis.
- Posaconazole showed promise in salvage therapy for serious fungal infections.
- Randomized controlled studies support posaconazole's prophylactic efficacy in severely immunocompromised patients.
Conclusions:
- Posaconazole exhibits wide-spectrum antifungal activity.
- Posaconazole has a favorable toxicity profile.
- Posaconazole is an important addition to the antifungal armamentarium.
Related Concept Videos
Antifungal Agents
Antiprotozoal Agents
Candidiasis
Cryptococcal Meningitis
Fungal Group Zygomycota
Fungal Phylum Microsporidia
